Next Article in Journal
The Actin Binding Protein Plastin-3 Is Involved in the Pathogenesis of Acute Myeloid Leukemia
Next Article in Special Issue
Conversion Surgery with HIPEC for Peritoneal Oli-gometastatic Gastric Cancer
Previous Article in Journal
Should All Patients With HR-Positive HER2-Negative Metastatic Breast Cancer Receive CDK 4/6 Inhibitor As First-Line Based Therapy? A Network Meta-Analysis of Data from the PALOMA 2, MONALEESA 2, MONALEESA 7, MONARCH 3, FALCON, SWOG and FACT Trials
Previous Article in Special Issue
Mutation in DNA Polymerase Beta Causes Spontaneous Chromosomal Instability and Inflammation-Associated Carcinogenesis in Mice
Review

Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Gastric Cancer

Division of Surgical Oncology, 1365B Clifton Road NE, Suite B4000, Atlanta, GA 30322, USA
*
Author to whom correspondence should be addressed.
Cancers 2019, 11(11), 1662; https://doi.org/10.3390/cancers11111662
Received: 23 September 2019 / Revised: 21 October 2019 / Accepted: 24 October 2019 / Published: 26 October 2019
(This article belongs to the Special Issue Recent Advances in Gastric Cancer)
The management of peritoneal metastases from gastric cancer origin has evolved considerably over the last three decades with the establishment of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) as efficacious therapies in carefully selected patients. Other approaches such as the use of prophylactic/adjuvant HIPEC in patients who are considered high-risk and those with positive peritoneal cytology will benefit from additional data before being adopted into routine clinical practice. Lastly, there are new and emerging intraperitoneal chemotherapy techniques such as early post-operative intraperitoneal chemotherapy (EPIC) for residual microscopic disease, and pressurized intraperitoneal aerosolized chemotherapy (PIPAC) for patients with advanced unresectable peritoneal carcinomatosis, which are currently under evaluation in clinical trials. The following review outlines the natural history of gastric cancer, currently available neoadjuvant and adjuvant therapies for resectable disease, and existing evidence supporting various approaches to CRS and intraperitoneal chemotherapy. View Full-Text
Keywords: Cytoreductive surgery; intraperitoneal chemotherapy; peritoneal metastases; gastric cancer Cytoreductive surgery; intraperitoneal chemotherapy; peritoneal metastases; gastric cancer
MDPI and ACS Style

Gamboa, A.C.; Winer, J.H. Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Gastric Cancer. Cancers 2019, 11, 1662. https://doi.org/10.3390/cancers11111662

AMA Style

Gamboa AC, Winer JH. Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Gastric Cancer. Cancers. 2019; 11(11):1662. https://doi.org/10.3390/cancers11111662

Chicago/Turabian Style

Gamboa, Adriana C., and Joshua H. Winer 2019. "Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Gastric Cancer" Cancers 11, no. 11: 1662. https://doi.org/10.3390/cancers11111662

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop